GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Tianjin TEDA Biomedical Engineering Co Ltd (HKSE:08189) » Definitions » EBIT

Tianjin TEDA Biomedical Engineering Co (HKSE:08189) EBIT : HK$-7.7 Mil (TTM As of Jun. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Tianjin TEDA Biomedical Engineering Co EBIT?

Tianjin TEDA Biomedical Engineering Co's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2024 was HK$0.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-7.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Tianjin TEDA Biomedical Engineering Co's annualized ROC % for the quarter that ended in Jun. 2024 was 0.00%. Tianjin TEDA Biomedical Engineering Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 0.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Tianjin TEDA Biomedical Engineering Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -0.66%.


Tianjin TEDA Biomedical Engineering Co EBIT Historical Data

The historical data trend for Tianjin TEDA Biomedical Engineering Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin TEDA Biomedical Engineering Co EBIT Chart

Tianjin TEDA Biomedical Engineering Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -93.67 -57.33 -48.21 -19.71 -7.48

Tianjin TEDA Biomedical Engineering Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.89 -6.23 -5.20 11.62 -

Competitive Comparison of Tianjin TEDA Biomedical Engineering Co's EBIT

For the Agricultural Inputs subindustry, Tianjin TEDA Biomedical Engineering Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin TEDA Biomedical Engineering Co's EV-to-EBIT Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Tianjin TEDA Biomedical Engineering Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tianjin TEDA Biomedical Engineering Co's EV-to-EBIT falls into.



Tianjin TEDA Biomedical Engineering Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-7.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tianjin TEDA Biomedical Engineering Co  (HKSE:08189) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Tianjin TEDA Biomedical Engineering Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=0 * ( 1 - 0% )/( (315.719 + 318.264)/ 2 )
=0/316.9915
=0.00 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Tianjin TEDA Biomedical Engineering Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (109.014 + max(23.454, 0)) + (118.043 + max(27.656, 0)) )/ 2 )
=0/( ( 132.468 + 145.699 )/ 2 )
=0/139.0835
=0.00 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.6 + 98.94 + 82.896) - (44.985 + 0 + 122.997)
=23.454

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.56 + 86.4 + 80.239) - (41.11 + 0 + 108.433)
=27.656

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Tianjin TEDA Biomedical Engineering Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-7.693/1169.101
=-0.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tianjin TEDA Biomedical Engineering Co EBIT Related Terms

Thank you for viewing the detailed overview of Tianjin TEDA Biomedical Engineering Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin TEDA Biomedical Engineering Co Business Description

Traded in Other Exchanges
N/A
Address
No. 80, The 4th Avenue, 9th Floor, Block A2, Tianda Hi-Tech Park, TEDA Tianjin, Tianjin, CHN
Tianjin TEDA Biomedical Engineering Co Ltd is engaged in the research, development, and commercialization of biological compound fertilizers, providing elderly and health care services. It operates in two segments namely; biological compound fertilizers products, and elderly care and health care services. The company generates a majority of its revenue from the Fertilisers products segment which is engaged in manufacturing and selling biological compound fertiliser products, including active fertiliser, mixture with nitrogen, phosphorus, and potassium with various formulas, providing warehousing services, and processing and licensing of the fertiliser products. The People's Republic of China is the primary geographical market for the company.
Executives
Long Ortiz 2101 Beneficial owner

Tianjin TEDA Biomedical Engineering Co Headlines

No Headlines